Chromosomal alterations in paired gastric adenomas and carcinomas

Yonsei University, Sŏul, Seoul, South Korea
American Journal Of Pathology (Impact Factor: 4.6). 03/2001; 158(2):655-62. DOI: 10.1016/S0002-9440(10)64007-2
Source: PubMed

ABSTRACT Gastric adenoma is a precancerous lesion of the stomach and its malignant transformation is thought to result from accumulative series of gene alterations. The aim of this study was to determine the pattern of chromosomal changes during gastric carcinogenesis. Pairs of adenoma and carcinoma tissues from 15 gastrectomy cases containing both adenomas and carcinomas in the same (adjacent pairs, 6 cases) and different (non-adjacent pairs, 9 cases) lesions, were analyzed for chromosomal alterations of 39 non-acrocentric chromosomal arms by comparative genomic hybridization (CGH). CGH analysis identified frequent chromosomal alterations in most of the gastric adenomas (14/15, 93%) and all of the carcinomas. The mean number of chromosomal alterations was higher in carcinoma (5.5 for adenoma and 11.7 for carcinoma; P = 0.006, by nonparametric Wilcoxon's test). Losses on the short arm of chromosome 17 were most common in both adenomas (43%) and carcinomas (67%). The pattern of chromosomal alterations in paired gastric adenomas and carcinomas showed greater similarity compared to the non-case pairs and this similarity was increased in the adjacent pairs. Deletion mapping analysis on chromosome 17p also demonstrated that the conserved deletion area was more frequent in the adjacent pairs. Among these 6 adjacent pairs, all had common deletion areas. In contrast, among the 9 non-adjacent pairs, 2 (22%) had common area of deletion, 5 (56%) showed deletion only in the carcinoma, and the remaining 2 (22%) had no deletion on 17p, suggesting diverse genetic changes might be involved in the multiple tumor formation. Our results that common clonal genetic changes between adjacent pairs of gastric adenomas and carcinomas and accumulated genetic changes in the carcinomas provide evidences for the stepwise mode of gastric carcinogenesis through the accumulation of a series of genetic alterations.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: AIM:To study proliferation and apoptosis in gastric carcinoma (GC) and precancerous lesions and expression of their regu- lating genes. METHODS:Total 24 cases of GC, 14 dysplasia (DP), 24 chronic gastritis (10 superfical gastritis, SG, 14 atrophic gastritis, AG) and 32 intestinal metaplasia (IM) were studied by histopathological, immunohistochemical techniques with Ki67, P53 and Bcl-2 antibodies, and by TUNEL for apoptosis. Proliferation index (PI), apoptosis index (AI), apoptosis/ proliferation ratio, apoptosis degree and positive percent of P53 and Bcl-2 were counted. RESULTS:The PI of GC, DP, IM, AG were 12.4±6.8 %, 6.4±4.2 %, 6.6±3.4 %, 3.8±2.9 % respectively. There was a significant difference between SG and GC, DP, IM, and AG (P
  • Cancer Letters 05/2004; DOI:10.1016/S0304-3835(04)00240-X · 5.02 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: RhoB is expressed during tumor cell proliferation, survival, invasion, and metastasis. In malignant progression, the expression levels of RhoB are commonly attenuated. RhoB is known to be linked to the regulation of the PI3K/Akt survival pathways. Based on aliphatic amido-quaternary ammonium salts that induce apoptosis via up-regulation of RhoB, we synthesized novel aliphatic sulfonamido-quaternary ammonium salts. These new synthetic compounds were evaluated for their biological activities using an in vitro RhoB promoter assay in HeLa cells, and in a growth inhibition assay using human cancer cell lines including PC-3, NUGC-3, MDA-MB-231, ACHN, HCT-15, and NCI-H23. Compound 5b (ethyl-dimethyl-{3-[methyl-(tetradecane-1-sulfonyl)-amino]-propyl}-ammonium; iodide) was the most promising anticancer agent in the series, based upon the potency of growth inhibition and RhoB promotion. These new aliphatic sulfonamido-quaternary ammonium salts could be a valuable series for development of new anticancer chemotherapeutic agents.
    European Journal of Medicinal Chemistry 09/2013; 69C:670-677. DOI:10.1016/j.ejmech.2013.09.022 · 3.43 Impact Factor

Full-text (2 Sources)

Available from
Jun 5, 2014